Submit Manuscript  

Article Details

Comparison of (+)- and (-)-Hemipalmitoylcarnitinium as Inhibitors of Hepatic Mitochondrial Carnitine Palmitoyltransferases in Diabetic Rats

[ Vol. 1 , Issue. 5 ]


P. S. Savle, N. E. Neptune, Y. Yang, J. H. Rouden, B. L. Kite, E. W. Sugandhi, R. V. Macri, K. Kashfi and R. D. Gandour   Pages 445 - 453 ( 9 )


The syntheses of (R)- and (S)-norcarnitine ethyl esters are described starting with an optimized, chiral chemical reduction of ethyl 4-chloroacetoacetate followed by azide substitution, reduction, and dimethylation. The reaction of (R)- and (S)-norcarnitine ethyl esters with 1-bromoheptadecan-2-one gives (+)- and (-)-6-[(methoxycarbonyl)methyl]-2- pentadecyl-4,4-dimethylmorpholinium bromide, respectively, which hydrolyzes to (+)- and (-)-6-(carboxylatomethyl)-2- pentadecyl-4,4-dimethylmorpholinium (hemipalmitoylcarnitinium, (+)- and (-)-HPC), respectively, upon treatment with a hydroxide resin. (+)- and (-)-HPC are reversible active-site directed inhibitors of hepatic mitochondrial CPTs. Both stereoisomers inhibit CPT I and CPT II in control and streptozotocin diabetic rat to the same extent (Imax = 100%). Using intact mitochondria (CPT I), I50 values for (-)-HPC and (+)-HPC were 15.5 μM and 47.5 μM, respectively. The I50 values for CPT II were 6.7 μM and 38.5 μM for (-)-HPC and (+)-HPC, respectively. The mode of inhibition was uncompetitive for CPT I with respect to acyl-CoA. The apparent Ki for (-)-HPC is about 5 μM. These data suggest that (-)-HPC may be useful for further evaluation as an antidiabetic agent.


carnitine palmitoyltransferase, antidiabetic agent, chiral synthesis, enzyme inhibition


Department of Chemistry (MC 0212) Virginia Tech, Blacksburg, VA, USA.

Read Full-Text article